
Topical gel for psoriasis generates promising results
A European study’s preliminary findings suggest that psoriasis treatments with Daivobet gel (calcipotriol/betamethasone dipropionate, LEO Pharma) result in significant improvement in disease severity and patient preference.
A European study’s
A statement issued by Danish firm LEO Pharma states that the study - “one of the largest and longest clinical trials ever conducted for a topical treatment in
The study assessed 1,795 patients with mild-to-severe psoriasis across Europe who had not responded sufficiently to previous topical treatment. Following eight weeks of treatment with calcipotriol/
Lead investigator
According to the LEO Pharma statement, the trial is the first to assess whether a tailored patient-education and support program can improve adherence to topical therapy and increase clinical effectiveness for psoriasis patients.
Full data from the 64-week study are expected to be released in 2015. The study’s preliminary results were published in the
Reference: Reich K, Zschocke I, Bachelez H, et al. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol. 26 Oct 2014 [Epub ahead of print]
Related content:
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















